Collegium製藥 COLL 深 滬
已收盤 02-06 16:00:00 美东时间
47.61
+0.690
+1.47%
華盛通- 最 高48.045
- 今 開47.48
- 成交量 25.90万股
- 最 低 47.045
- 昨 收 46.92
- 總市值 15.05亿
- 52周最高 50.7866
- 市盈率 靜 25.64
- 換手率 0.82%
- 52周最低 23.23
- 委 比 -5.08%
- 總股本 3161.10万
- 歷史最高 50.7866
- 量 比 0.76
- 振 幅 2.13%
- 歷史最低 7.37
- 每 手 1
- 風險率 7.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
What 6 Analyst Ratings Have To Say About Collegium Pharmaceutical
Collegium Pharmaceutical (NASDAQ:COLL) underwent analysis by 6 analysts in the ...
01-09 20:01
HC Wainwright & Co. Reiterates Buy on Collegium Pharmaceutical, Raises Price Target to $60
HC Wainwright & Co. analyst Brandon Folkes reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and raises the price target from $46 to $60.
01-09 19:38
Needham Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $56
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and raises the price target from $48 to $56.
01-09 18:30
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Barclays Initiates Coverage On Collegium Pharmaceutical with Overweight Rating, Announces Price Target of $58
Barclays analyst Glen Santangelo initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight rating and announces Price Target of $58.
2025-12-09 23:36
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Collegium Pharmaceutical shares are trading higher after the company reported better-than-expected Q3 financial results and raised FY2025 revenue outlook.
Collegium Pharmaceutical shares are trading higher after the company reported b...
2025-11-06 20:40
Collegium Pharmaceutical Q3 Adj. EPS $2.25 Beats $2.04 Estimate, Sales $209.361M Beat $189.118M Estimate
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $2.25 per share which beat the analyst consensus estimate of $2.04 by 10.08 percent. This is a 39.75 percent increase over earnings of $1.61 per share
2025-11-06 20:36
